Burström, K.* ; Teni, F.S.* ; Gerdtham, U.G.* ; Leidl, R. ; Helgesson, G.* ; Rolfson, O.* ; Henriksson, M.*
Experience-based Swedish TTO and VAS value sets for EQ-5D-5L health states.
Pharmacoeconomics 38, 839-856 (2020)
Kähm, K. ; Laxy, M. ; Schneider, U.* ; Holle, R.
Exploring different strategies of assessing the economic impact of multiple diabetes-associated complications and their interactions: A large claims-based in Germany.
Pharmacoeconomics 37, 63-74 (2019)
Laxy, M. ; Schöning, V.M. ; Kurz, C.F. ; Holle, R. ; Peters, A. ; Meisinger, C. ; Rathmann, W.* ; Mühlenbruch, K.* ; Kähm, K.
Performance of the UKPDS outcomes model 2 for predicting death and cardiovascular events in patients with type 2 diabetes mellitus from a German Population-Based Cohort.
Pharmacoeconomics 37, 1485-1494 (2019)
Stollenwerk, B. ; Iannazzo, S.* ; Akehurst, R.* ; Adena, M.* ; Briggs, A.* ; Dehmel, B.* ; Parfrey, P.* ; Belozeroff, V.*
A decision-analytic model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet.
Pharmacoeconomics 36, 603-612 (2018)
Iglesias, C.P.* ; Thompson, A.* ; Rogowski, W.H. ; Payne, K.*
Reporting guidelines for the use of expert judgement in model-based economic evaluations.
Pharmacoeconomics 34, 1161-1172 (2016)
Mensch, A.* ; Stock, S.* ; Stollenwerk, B. ; Müller, D.*
Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
Pharmacoeconomics 33, 271-283 (2015)
Rogowski, W.H. ; Payne, K.* ; Schnell-Inderst, P.* ; Manca, A.* ; Rochau, U.* ; Jahn, B.* ; Alagoz, O.* ; Leidl, R. ; Siebert, U.*
Concepts of 'personalization' in personalized medicine: Implications for economic evaluation.
Pharmacoeconomics 33, 49-59 (2015)
Schremser, K. ; Rogowski, W.H. ; Adler-Reichel, S.* ; Tufman, A.L.* ; Huber, R.M. ; Stollenwerk, B.
Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany.
Pharmacoeconomics 33, 1215-1228 (2015)
Hatz, M.H.M. ; Schremser, K. ; Rogowski, W.H.
Is individualized medicine more cost-effective? A systematic review.
Pharmacoeconomics 32, 443-455 (2014)
Hatz, M.H.M. ; Leidl, R. ; Yates, N.A. ; Stollenwerk, B.
A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Pharmacoeconomics 32, 377-393 (2014)
Heimeshoff, M.* ; Hollmeyer, H.* ; Schreyögg, J. ; Tiemann, O. ; Staab, D.*
Cost of illness of cystic fibrosis in Germany: Results from a large cystic fibrosis centre.
Pharmacoeconomics 30, 763-777 (2012)
Menn, P. ; Leidl, R. ; Holle, R.
A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.
Pharmacoeconomics 30, 825-840 (2012)
Blankart, C.R.B. ; Stargardt, T. ; Schreyögg, J.
Availability of and access to orphan drugs: An international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
Pharmacoeconomics 29, 63-82 (2011)
Leidl, R. ; Reitmeir, P.
A value set for the EQ-5D based on experienced health states: Development and testing for the German population.
Pharmacoeconomics 29, 521-534 (2011)
Menn, P. ; Holle, R.
Comparing three software tools for implementing markov models for health economic evaluations.
Pharmacoeconomics 27, 745-753 (2009)
Kreck, S.* ; Klaus, J.* ; Leidl, R. ; von Tirpitz, C.* ; Konnopka, A.* ; Matschinger, H.* ; König, H.H.*
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: Cost-utility analysis using a Markov model.
Pharmacoeconomics 26, 311-328 (2008)
Bos, J.M.* ; Rümke, H.C.* ; Welte, R. ; Spanjaard, L.* ; van Alphen, L.* ; Postma, M.J.*
Combination vaccine against invasive meningococcal B and pneumococcal infections: Potential epidemiological and economic impact in The Netherlands.
Pharmacoeconomics 24, 141-153 (2006)
Stark, R.G. ; König, H.-H.* ; Leidl, R.
Costs of inflammatory bowel disease in Germany.
Pharmacoeconomics 24, 797-814 (2006)
Welte, R. ; Trotter, C.* ; Edmunds, W.* ; Postma, M.J.* ; Beutels, P.*
The Role of Economic Evaluation in Vaccine Decision Making.
Pharmacoeconomics 23, 855-874 (2005)
Welte, R. ; Feenstra, T.* ; Jager, H.* ; Leidl, R.
A decision chart for assessing and improving the transferability of economic evaluation results between countries.
Pharmacoeconomics 22, 857-876 (2004)